Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 22;143(1):46-56.
doi: 10.1093/bmb/ldac017.

Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis

Filippo Migliorini  1 , Giorgia Colarossi  1 , Jörg Eschweiler  1 , Francesco Oliva  2 , Arne Driessen  1 , Nicola Maffulli  2   3   4
Affiliations

Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis

Filippo Migliorini et al. Br Med Bull. .

Abstract

Introduction: Corticosteroid-induced osteoporosis (CIO) is the most common type of secondary osteoporosis, leading to fractures, and increased morbidity and mortality.

Source of data: Pubmed, EMBASE, Scopus and Google Scholar databases.

Areas of agreement: Prolonged glucocorticoids administration leads to secondary osteoporosis.

Areas of controversy: The optimal management for CIO is controversial.

Growing points: The present study compared bone mineral density, fractures and adverse events in patients undergoing treatment with risedronate, alendronate, zoledronate, denosumab or etidronate for CIO.

Areas timely for developing research: For selected patients with CIO, alendronate performed better overall. These results must be interpreted within the limitations of the present study.

Level of evidence: I, Bayesian network meta-analysis of randomized clinical trials.

Keywords: BMD; alendronate; corticosteroid; drugs; fracture; osteoporosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart of the literature search.
Fig. 2
Fig. 2
Methodological quality assessment.
Fig. 3
Fig. 3
Overall results of the network comparisons concerning BMD.
Fig. 4
Fig. 4
Overall results of the network comparisons concerning fractures.
Fig. 5
Fig. 5
Overall results of the network comparisons concerning adverse events.
See this image and copyright information in PMC

References

    1. Eriksen EF, Diez-Perez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone 2014;58:126–35. - PubMed
    1. Anastasilakis AD, Polyzos SA, Makras P. Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol 2018;179:R31–45. - PubMed
    1. Chandran T, Venkatachalam I. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. Singapore Med J 2019;60:364–78. - PMC - PubMed
    1. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010–8. - PubMed
    1. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009;122:S14–21. - PubMed

Publication types

MeSH terms